Properties of monocytes generated from haematopoietic CD34+ stem cells from bone marrow of colon cancer patients by Stec, Małgorzata et al.
ORIGINAL ARTICLE
Properties of monocytes generated from haematopoietic CD34+
stem cells from bone marrow of colon cancer patients
Malgorzata Stec • Jarosław Baran • Rafał Szatanek • Bo _zenna Mytar •
Marzena Lenart • Antoni Czupryna • Antoni Szczepanik • Maciej Siedlar •
Marek Zembala
Received: 1 June 2012 / Accepted: 7 November 2012 / Published online: 24 November 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Monocytes exhibit direct and indirect antitu-
mour activities and may be potentially useful for various
forms of adoptive cellular immunotherapy of cancer.
However, blood is a limited source of them. This study
explored whether monocytes can be obtained from bone
marrow haematopoietic CD34? stem cells of colon cancer
patients, using previously described protocol of expansion
and differentiation to monocytes of cord blood-derived
CD34? haematopoietic progenitors. Data show that in two-
step cultures, the yield of cells was increased approxi-
mately 200-fold, and among these cells, up to 60 % of
CD14? monocytes were found. They consisted of two
subpopulations: CD14??CD16? and CD14?CD16-, at
approximately 1:1 ratio, that differed in HLA-DR expres-
sion, being higher on the former. No differences in
expression of costimulatory molecules were observed, as
CD80 was not detected, while CD86 expression was
comparable. These CD14? monocytes showed the ability
to present recall antigens (PPD, Candida albicans) and
neoantigens expressed on tumour cells and tumour-derived
microvesicles (TMV) to autologous CD3? T cells isolated
from the peripheral blood. Monocytes also efficiently
presented the immunodominant HER-2/neu369–377 peptide
(KIFGSLAFL), resulting in the generation of specific
cytotoxic CD8? T lymphocytes (CTL). The CD14??CD16?
subset exhibited enhanced cytotoxicity, though nonsignif-
icant, towards tumour cells in vitro. These observations
indicate that generation of monocytes from CD34? stem
cells of cancer patients is feasible. To our knowledge, it
is the first demonstration of such approach that may open
a way to obtain autologous monocytes for alternative
forms of adaptive and adoptive cellular immunotherapy
of cancer.
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Introduction
Monocytes/macrophages are important players in the host
response to the growing tumour, with both enhancing and
inhibitory capacities [1–3]. Despite the former, they are
still regarded as potential cells that can be used for cellular
forms of cancer immunotherapy. Blood monocytes isolated
by cytapheresis have been used as a source of effector
cytotoxic cells with rather disappointing results [4]. Such
strategies require large numbers of monocytes, sometimes
their activation, and are based on their direct cytotoxic
activity. It is well established that peripheral blood (PB)
monocytes exhibit significant cytotoxicity in vitro, which is
mediated by some cytokines, for example, surface bound
tumour necrosis factor (TNF), and release of reactive
nitrogen and oxygen intermediates (RNI and ROI, respec-
tively) [5–7]. Furthermore, PB monocytes can also act as
antigen-presenting cells (APC) [8] which may be useful for
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presentation of tumour-associated antigens (TAA) for the
generation of cytotoxic T lymphocytes used in adoptive
immunotherapy [9]. Along this way, microvesicles (MV)
that are shed by many cells of the body, in particular these
rapidly proliferating, are playing an important role in cell
to cell communication [10]. We have previously shown
that tumour-derived MV (TMV) carry some determinants
of the tumour cells and transfer them to monocytes [11]. It
is also known that TMV express TAA [12]. Therefore,
TMV may be a useful source of neoantigens to be pre-
sented to cytotoxic T cells.
Among two main subpopulations of PB monocytes,
CD14??CD16- and CD14?CD16?? [13], the latter pos-
sess an enhanced antitumour activity, as judged by an
increased production of TNF, interleukin (IL)-12, ROI and
cytotoxic activity in vitro [14]. However, CD14?CD16??
cells are the minor population consisting of approximately
5–10 % of total monocytes [13, 15, 16], and nonprolifer-
ating cells may be very limited in numbers that are required
for adoptive immunotherapy of cancer [4]. We have pre-
viously described the protocol for generation of monocytes
from cord blood (CB) haematopoietic CD34? progenitors
which may give rise to potentially unlimited numbers of
monocytes, as up to 1000-fold increase in cells in com-
parison with the initial inoculum was obtained, and among
them up to 60 % of CD14? cells consisting of two novel
subsets CD14??CD16? and CD14?CD16- were found.
They differed not only in the CD14 but also in other
determinants expression and functional activity [17].
In the present study, the attempts were undertaken to
obtain monocytes from bone marrow (BM) haematopoietic
CD34? stem cells of patients with colon cancer and to
determine their immunophenotype and some functional
activities. This paper shows that monocytes with similar
characteristics as CB CD34? cell-derived monocytes,
consisting of CD14??CD16? and CD14?CD16- subsets,
can be generated and exhibited APC capacity and cyto-
toxicity against tumour cells.
Materials and methods
Bone marrow biopsy and isolation of CD34? cells
Bone marrow from patients with colorectal cancer (Duke’s
C stage) was obtained by needle aspiration from the iliac
crest, after written consents from the patients. The 15
patients (6 females and 9 males) with mean age
66 ± 14 years, before surgery and without any previous or
current treatment were studied. Aspirates were suspended
in saline, and mononuclear cells from them and from
peripheral blood (PBMC) were isolated accordingly by
standard density-gradient centrifugation (Lymphocyte
Separation Medium 1077, PAA Laboratories GmbH,
Pasching, Austria). Then the CD34? cells were isolated
from PBMC using the EasySep Human CD34 Positive
Selection Kit (StemCell Technologies, Vancouver, Canada),
based on magnetic cell sorting. The mean number of
CD34? cells recovered was 1.6 9 105 ± 1.4 9 105. The
study was approved by the local Jagiellonian University
Ethical Committee (No. KBET/86/B/2007 and KBET/193/
B/2011).
Generation of monocytes
CD34? cells were expanded and differentiated to mono-
cytes in two-step cultures in the expansion and differenti-
ation media, each step 7–10 days, as previously described
[17].
Immunophenotyping
The following anti-human monoclonal antibodies (mAbs)
were used: anti-CD14 allophycocyanin (APC)-conjugated,
anti-CD16 and anti-HLA-DR, both phycoerythrin (PE)-
conjugated, anti-CD80 and anti-CD86, both fluorescein
isothiocyanate (FITC)-conjugated (all from BD Pharmin-
gen, San Diego, CA). In parallel, staining with appropriate
isotype-matched mouse immunoglobulins (BD Pharmin-
gen) were used as negative controls. After incubation for
30 min at 4 C with mAbs or isotype controls, the cells
were washed, resuspended in 0.3 ml of PBS containing
0.1 % sodium azide and analysed by flow cytometry
(FACS Canto, BD Biosciences Immunocytometry Sys-
tems, San Jose, CA) using FACS DiVa v. 5.1 software. List
mode data for 20,000 events were acquired, and statistical
analysis was performed according to the fluorescence
intensity of cells stained with appropriate isotype controls.
Isolation of monocytes and their subpopulations
Cells cultured in the differentiation medium were har-
vested, washed, and suspended at the concentration of
10 9 106/ml. After staining with anti-CD14 APC and anti-
CD16 PE-conjugated mAbs, the cells were sorted using a
100 lm nozzle tip in FACS Aria II (BD Biosciences) into
CD14? monocytes (total population) and CD14??CD16?
and CD14?CD16- subpopulations. Sorted cells were col-
lected into polystyrene Falcon 2057 tubes (BD Biosci-
ences) precoated with foetal bovine serum (FBS, Gibco,
Paisley, UK), to avoid plastic charging and cell attachment
to the wall. The cells were washed and suspended in RPMI
1640 medium (Sigma, St. Louis, MO), supplemented with
gentamycin (50 lg/ml), glutamine (2 mM) and 5 % FBS
(all from Gibco).
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Isolation of T lymphocytes
The CD3? cells were isolated from PBMC (obtained as
above) using the EasySep Human CD3 Positive Selection
Kit (StemCell Technologies) based on magnetic cell sort-
ing. Isolated CD3? lymphocytes were suspended in Serum
Free Type Cell Freezing Medium (Bambanker, Lympho-
tec, Tokyo, Japan) and stored at -80 C until use.
Tumour cell lines and tumour-derived microvesicles
(TMV)
Human pancreatic carcinoma (HPC-4) cell line established
in this laboratory [18] and DeTa (colon carcinoma) were
cultured and passaged as previously described [19], except
that FBS was deprived of MV by centrifugation at
50,0009g for 1 h. TMV from HPC-4 cells (TMVHPC) were
obtained as previously described [11]. Briefly, supernatants
from well-grown cell cultures were collected and spun
down at 2,0009g for 20 min to remove cell debris. Then
supernatants were again pelleted (RC28S centrifuge,
Sorvall, Newton, CT) at 50,0009g for 1 h at 4 C. Pellets
were washed several times in RPMI 1640 to remove FBS
and finally resuspended in serum-free RPMI 1640 medium.
Quantification of TMV protein concentration was evalu-
ated by the Bradford method (BioRad, Hercules, CA). The
cells and TMVHPC were tested for the presence of HER-2/
neu using APC-labelled anti-HER-2/neu mAb (BD Bio-
sciences) and flow cytometry analysis (FACS Canto).
Antigen presentation
The CD34? cell-derived CD14? monocytes (1 9 104/well)
isolated by FACS sorting were cultured for 2 h in the
presence of recall antigens: purified protein derivative
(PPD, 25 lg/ml; Statenserum Institute, Copenhagen, Den-
mark) or Candida albicans (BioRad, Marnes-la-Coqunette´,
France), or c-irradiated (20 Gy) HPC-4 cells, or TMVHPC
(5 lg/ml final concentration) or specific TAA antigen–
HER2/neu immunodominant peptide KIFGSLAFL (5 lg/
ml) in flat-bottom 96-well plates (Sarstedt, Numbrecht,
Germany) in RPMI 1640 medium supplemented with
L-glutamine (2 mM), 10 % human AB serum and genta-
mycin (50 lg/ml, all from Gibco). Then, autologous T
cells, after thawing and washing three times in RPMI 1640
medium, were added (1 9 105/well). T lymphocytes alone
or with the appropriate stimulus and unstimulated cultures
were used in parallel as negative controls. Cells were
cultured in triplicates for 6 days at 37 C in 5 % CO2
atmosphere, with a 6 h terminal pulse of [3H]-thymidine
(1 lCi/well). Index of proliferation was calculated
according to the formula: cpm of 3H-thymidine incorpo-
ration in the stimulated culture/cpm of appropriate negative
control cultures. BM monocytes were generated, and T
lymphocytes were isolated only from the patients whose
PBMC proliferated in response to specified stimulants.
Detection of HER-2/neu-specific cytotoxic CD8? T
cells (CTL)
For the detection of HER-2/neu-specific CTL, only patients
positive for HLA-A2 antigens were selected. Expression of
HLA-A2 was determined by patients’ blood lymphocytes
staining, using PE-conjugated mouse anti-human HLA-A2
mAb or PE-conjugated isotype-matched mouse immuno-
globulins (both BD Pharmingen) as a negative control,
followed by lysis of erythrocytes (FACS Lysing Solution,
BD Biosciences) and flow cytometry analysis (FACS
Canto). Patients positive for HLA-A2 expression were
further tested for the presence of CTL specific to the
immunodominant HER-2/neu369–377 epitope. For this pur-
pose, whole blood samples were stained with PE-labelled
HLA-A*0201 pentamer complex (ProImmune Ltd., Oxford,
UK), folded around the HER-2/neu369–377-specific epitope.
As a negative control, staining with HLA-A*0201 negative
control pentamer (ProImmune) was used. The cells were
incubated with indicated pentamers for 30 min. at 20 C
followed by washing and staining with peridinin chloro-
phyll protein complex (PerCP)-conjugated anti-CD3 and
FITC-conjugated anti-CD8 mAb (BD Pharmingen) for
30 min. at 4 C in the dark. Then, the cells were washed
and erythrocytes were lysed (FACS Lysing Solution). After
additional washing, cells were analysed by flow cytometry
(FACS Canto). Data from a minimum 50,000 CD3? cells
were collected, and detection of more than 0.2 % HER-2/
neu pentamer-stained CD3? CD8? cells above the back-
ground was considered positive.
Generation of HER-2/neu-specific CTL
To check the ability of patients BM CD34? cell-derived
monocytes to induce HER-2/neu-specific CTL, the cells
from patients positive for primed HER-2/neu369–377 CTL
were used. T cells were isolated and stored, as described
above, until monocytes were generated. After thawing, T
cells (5 9 105/well) were cultured with 5 9 104 BM stem
cell-derived autologous CD14? monocytes, in the presence
of HER-2/neu369–377 peptide (KIFGSLAFL; 5 lg/ml, Pro-
Immune) in RPMI 1640 medium, supplemented with
L-glutamine (2 mM), 10 % human AB serum and genta-
mycin (50 lg/ml, all from Gibco). After 7 days of culture,
the level of HER-2/neu369–377-specific CTL was deter-
mined by pentamer staining and flow cytometry analysis,
as described above.
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Determination of cytotoxic activity
Cytotoxicity of monocytes and their subpopulations
towards HPC-4 and DeTa cells was determined as previ-
ously described [6]. Briefly, monocytes (5 9 104/well),
tumour cells (2 9 104/well) or their mixtures were cultured
in RPMI 1640 medium for 24 h. Then, the culture medium
was removed and 100 ll per well of MTT (2 mg/ml; 1, 3-
[4,5-dimetylthiazol-2-yl]-2,5-diphenyltetrazolium bromide,
Sigma) dye solution was added for 4 h. Formed formazan
was extracted with isopropyl alcohol (Fluka Chemie AG,
Buchs, Switzerland), containing 0.04 N HCL and its con-
tent determined by spectrophotometrical measurement of
absorbance using two different wavelengths: 570 and
630 nm. The percentage of cytotoxicity was calculated
according to the formula previously described [20]:

1  OD monocytes þ tumour cellsð Þ
OD monocytes aloneð Þ=OD tumour cells aloneð Þ 100
Statistical analysis
Nonparametric one-way ANOVA test with the Microcal
Origin software v. 5.0 (Northampton, MA) was used for
analysis. The differences were considered significant at
p \ 0.05.
Results
Immunophenotype of CD34? cell-derived monocytes
Following culture of CD34? cells in the expansion and dif-
ferentiation media, the number of cells increased approxi-
mately 200-fold (range 75–440) (Fig. 1a) with up to 60 %
of CD14? cells at day 20 (Fig. 1b). Among them,
CD14??CD16? and CD14?CD16- subsets in approximately
1:1 proportion were observed (Fig. 2a). Then, the expression
of costimulatory molecules on these subsets was determined.
The CD80 was not detected, CD86 was comparable on both
subsets, while significantly higher HLA-DR expression on
CD14??CD16? monocytes was observed (Fig. 2b, c).
Determination of HER-2/neu expression on HPC-4
cells and TMVHPC
In order to check whether tumour cells and their TMV used
exhibit TAA, expression of HER-2/neu was analysed by
flow cytometry. Figure 3a shows that almost all HPC-4
cells expressed HER-2/neu. In contrast, its expression on
TMVHPC was markedly lower when compared to the cells
they originated from (Fig. 3b). Furthermore, both HPC-4
cells and to a lesser extend TMVHPC expressed MUC-1 and
contained HER-2/neu, MAGE-1,3 and MUC-1 mRNA
(data not shown). We concluded that both the cells and
their TMV may be used as a source of TAA.
Proliferation of T lymphocytes in response to recall
antigens or TAA
First, to validate the occurrence of T lymphocytes priming,
we studied the response of patients’ PBMC to recall anti-
gens (PPD, Candida), c-irradiated HPC-4 cells or TMVHPC.
For further studies, only T lymphocytes and BM CD34?
cells from patients whose PBMC responded to the stimu-
lants were used. PBMC from 8 control subjects did not
respond to HPC-4 and TMVHPC (data not shown). The
autologous T lymphocytes isolated from PB of cancer
patients were added to CD34? cell-derived CD14?
monocytes and preexposed to recall antigens, c-irradiated
HPC-4 cells, and TMVHPC. Figure 4 shows that patients’ T
lymphocytes responded to recall antigens when cultured
with autologous monocytes. The cells also proliferated
following stimulation with HER-2/neu-positive HPC-4
cells or TMVHPC. T lymphocytes alone cultured in the
presence of stimulants did not proliferate. It was concluded
that CD34? cell-derived monocytes from cancer patients
are able to present recall antigens and TAA to autologous T
cells.
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Generation of HER-2/neu369–377-specific CTL
As the HER-2/neu-derived peptides, naturally processed as
TAA, are recognized by tumour-specific, HLA-A2-
restricted CTL in colorectal cancer [21], in the next set of
experiments we evaluated the proliferative response of T
cells stimulated with HER2/neu369–377 immunodominant
peptide in the presence of patients’ BM CD34? cell-
derived monocytes as APC. For this part of study, only
patients positive for HLA-A2 expression and for the
occurrence of primed CTL specific to the immunodominant
HER-2/neu369–377 epitope in the blood were selected. This
group contained four patients whose level of HER-2/
neu-specific CTL in the blood exceeded 0.2 % (range
0.25–1.2 %). T cells isolated from these patients were
cultured with population of autologous CD14? BM CD34?
cell-derived monocytes and stimulated with HER-2/
neu369–377 peptide (KIFGSLAFL). After 7 days of culture,
proliferation index increased (Fig. 5a). Simultaneously, the
level of peptide-specific CTL was determined by flow
cytometry (Fig. 5b) and found to be significantly increased
in cultures of monocytes with T cells, as compared to
PBMC (Fig. 5c). This indicates that BM CD34? cell-
derived CD14? monocytes induced propagation of HER2/
neu-specific CTL.
Cytotoxicity
The total population of monocytes (CD14? cells), used at
different doses, exhibited substantial spontaneous cytotoxicity
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towards HPC-4 and DeTa cancer cells (Fig. 6). The CD14??
CD16? monocytes showed slightly higher cytotoxic/cytostatic
activity in comparison with total population of monocytes
or their CD14?CD16- subset, though the differences were
statistically not significant.
Discussion
The present observations clearly demonstrate the feasibility
of in vitro generation of monocytes from BM CD34?
haematopoietic stem cells of colon cancer patients. This
model study was limited to a few patients and a small
volume of BM aspirates that were available. We have used
the protocol that was elaborated for production of mono-
cytes from CB haematopoietic CD34? stem cells, which
enabled up to 1000-fold increase in cultured cells among
which up to 60 % were CD14? monocytes, and included
the two-step cultures of the expansion and differentiation.
These monocytes consisted of novel CD14??CD16? and
CD14?CD16- subpopulations with the ratio 1:2 and were
clearly different from PB monocytes subsets by phenotype
and functions [17]. The use of BM CD34? cells from
cancer patients also led to the production of up to 60 %
CD14? monocytes containing these subsets, however,
occurring at the ratio 1:1. The reason for the differences in
the ratios of the monocyte subsets generated from BM and
CB CD34? cells are unknown but may be due to the initial
kinetic state of these cells or their level of lineage com-
mitment [22]. These subsets showed similar expression of
costimulatory molecule CD86, the lack of CD80 and an
enhanced expression of HLA-DR detected mostly on
CD14??CD16? monocytes. The latter finding is similar to
this CB monocyte subset, which shows an increased allo-
stimulatory capacity [17] and PB CD14?CD16?? sub-
population [14]. The increased expression of HLA-DR may
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Fig. 5 Generation of HER-2/neu-specific CD8? T cells in cultures of
BM CD34? cell-derived monocytes with autologous T cells from
colon cancer patients, stimulated with HER-2/neu peptide. a Prolif-
eration index of T cells in cultures with autologous BM CD34? cell-
derived monocytes from colon cancer patients stimulated with
HER-2/neu peptide (KIFGSLAFL). b Flow cytometry analysis of
the level of HER2/neu-specific CTL propagated in the presence of
BM CD34? cell-derived monocytes. T cells from HLA-A2-positive
patients were cultured with autologous BM CD34? cell-derived CD14?
monocytes in the presence of KIFGSLAFL peptide for 7 days, and after
staining with PE-conjugated HLA-A*0201 HER-2/neu369–377 pentamer
and anti-CD3 and anti-CD8 mAbs were analysed by FACS. CD8? T
lymphocytes were gated according to morphological (P1) and
phenotype marker characteristics (P2). Statistics was set according
to staining with HLA-A*0201-negative control pentamer. Data from
one representative analysis is shown. The initial level of HER-2/
neu369–377-specific CTL detected in PBMC of this patient was 0.25 %
(not shown). c The cumulative data of the initial levels of HER-2/
neu369–377-specific CTL detected in PBMC of HLA-A2-positive
patients and at the end of culture. Data from four performed
experiments are shown. * denotes significant difference from PBMC
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imply the higher potential of this subset to act as APC.
However, due to a small number of cells available, antigen-
presenting ability in respect to recall antigens and TAA
was studied only for the total population of obtained
monocytes. For determination of APC activity, patients
were selected on the basis of their PBMC response to these
antigens. The response of autologous T cells cultured with
monocytes to recall antigens was observed, which is sim-
ilar to PB monocytes [8]. Furthermore, such cultures
stimulated with tumour cells or TMV that express HER-2/
neu and possibly other neoantigens also responded. How-
ever, no proliferation was observed in cultures with the
addition of patients’ plasma, which is known to contain
TMV. This may be due to the relatively small concentra-
tion of TMV in the plasma [23]. Also, no response of T
cells cultured with autologous CB CD34? cell-derived
monocytes, used as control, to the stimuli employed was
detected, though these cultures were responding to poly-
clonal stimulation with anti-CD3 mAb (data not shown).
This may indicate that nonprimed CB T lymphocytes did
not proliferate in response to TAA. It is also supported by
the finding that patients, but not healthy donors PBMC,
responded to HPC-4 cells or TMVHPC (data not shown).
We wish to suggest that response of patients’ T lympho-
cytes to HPC-4 cells and TMVHPC is driven by TAA which
are expressed on their surface. Our data indicate that HER-
2/neu-specific CTL are detected in the blood of colon
cancer patients. These CTL were propagated in response to
the immunodominant HER-2/neu369–377 peptide presented
by patients’ autologous BM CD34? cell-derived mono-
cytes. This observation indicates that BM CD34? cell-
derived monocytes are potent APC and can be used for
expansion of TAA-specific CTL; however, the protocol for
more effective yield of expanded CTL needs to be further
elaborated as the increase in HER-2/neu369–377 CTL num-
ber in our study was not impressive when compared to
other studies using dendritic cells for stimulation with
tumour-derived peptides [24, 25]. It should be noted that
we used for their generation short-term cultures and low
initial numbers of T cells, which were available for the
study. In addition, we are aware of the fact that these cells
were determined only phenotypically and no functional
studies of CTL were performed, as the number of CTL
obtained was very low. These limited observations were
initiated only to proof the feasibility of this approach.
The question may arise, whether monocytes obtained
from BM-derived CD34? cells of healthy donors behave
differently or in the same way as those from cancer
patients. Due to ethical reasons, such controls were not
introduced into our study. However, the data obtained from
CB CD34? cell-derived monocytes suggest that the
absence of the response in their cultures with autologous T
cells is rather due to the lack of priming the latter and not to
the inability of monocytes to act as APC. This observation
also indirectly indicates the specificity of the response of
patients’ T cells.
It is known that human PB monocytes express sponta-
neous cytotoxicity towards tumour cells in vitro, which
is thought to be associated with their production of
TNF, ROI, RNI [6, 14, 26]. Among PB monocytes,
CD14?CD16?? subset (nonclassical monocytes) [13]
exhibits a higher cytotoxicity towards tumour cells [14].
The present data indicate that CD14? monocytes generated
from BM stem cells of colon cancer patients also show
substantial cytotoxicity, which was rather associated
(nonsignificantly) with CD14??CD16? subset. This makes
this subset similar to PB CD14?CD16?? subpopulation
[14]. Therefore, we cannot assign cytotoxicity of generated
monocytes to any particular subset. However, we wish to
suggest that in general, BM CD34? cell-derived monocytes
of cancer patients possess a higher cytotoxic/cytostatic
activity, around 40 %, while such monocytes generated
from CB around 20 % [27].
In summary, the data presented provide evidence that it
is possible to generate monocytes from BM haematopoietic
CD34? stem cells of cancer patients, which show the
ability to effectively present TAA or HER-2/neu369–377
dominant peptide and to act as cytotoxic cells against
tumour cells in vitro. It may open the way for generation,
potentially on large scale, autologous monocytes that can
be used in various forms of adaptive and adoptive cellular
immunotherapy of cancer.
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